606143-94-6

Basic information

• Product Name: Methyl 4-aMino-3-fluoro-2-((2-fluorophenyl)aMino)-5-nitrobenzoate
• Synonyms: Methyl 4-aMino-3-fluoro-2-((2-fluorophenyl)aMino)-5-nitrobenzoate
• CAS NO: 606143-94-6
• Molecular Formula: C₁₄H₁₁F₂N₃O₄
• Molecular Weight: 323.2516464
• Mol File: 606143-94-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 449.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.497±0.06 g/cm3(Predicted)
• PKA: -4.01±0.25(Predicted)
• CAS DataBase Reference: Methyl 4-aMino-3-fluoro-2-((2-fluorophenyl)aMino)-5-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-aMino-3-fluoro-2-((2-fluorophenyl)aMino)-5-nitrobenzoate(606143-94-6)
• EPA Substance Registry System: Methyl 4-aMino-3-fluoro-2-((2-fluorophenyl)aMino)-5-nitrobenzoate(606143-94-6)

Safety Data

• Hazardous Substances Data: 606143-94-6(Hazardous Substances Data)

Usage

General Description

Methyl 4-amino-3-fluoro-2-((2-fluorophenyl)amino)-5-nitrobenzoate is a chemical compound with a complex structure composed of carbon, hydrogen, nitrogen, oxygen, and fluorine atoms. It is commonly used in organic synthesis and pharmaceutical research. Methyl 4-aMino-3-fluoro-2-((2-fluorophenyl)aMino)-5-nitrobenzoate possesses fluorine and nitro groups, which may make it suitable for use in medicinal chemistry as a potential pharmaceutical ingredient. Its synthesis and properties make it a valuable tool in the development of new drugs and other applications in the field of chemical research.

Upstream product

• 284030-58-6 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 
• 348-54-9 2-Fluoroaniline 
• 284030-57-5 4-amino-2,3-difluoro-5-nitro-benzoic acid 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 197520-71-1 2,3,4-trifluoro-5-nitro-benzoic acid 

Relevant articles and documents

FORMS OF BINIMETINIB AND PROCESS FOR PREPARATION THEREOF

Amorphous forms of Binimetinib and processes for the preparation thereof.

COMBINATION THERAPY

The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)- amide or a pharmaceutically acceptable salt thereof and the IGFIR inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.